Enhanced Genomics, the biotechnology company pioneering 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, has announced that Katerina Leftheris has joined its board of directors.
Katerina’s appointment as a director forms part of the company’s ongoing strategy to expand its internal therapeutics pipeline for drug targets identified using its 3D multi-omics platform.
Most recently, Katerina was Chief Scientific Officer at a machine learning-based oral macrocycle drug development company, Vilya, and is on the board of directors and scientific advisory boards for several biotech companies focused on therapeutics development.
Bringing extensive experience, particularly in medicinal chemistry and drug discovery programmes, Katerina will support the executive team in driving development of Enhanced’s internal therapeutics pipeline for drug targets identified using its 3D multi-omics platform, GenLink.
Dietrich A Stephan, Executive Chair, Enhanced Genomics, said: “I am thrilled to welcome Katerina as the newest member of our board. Her exceptional expertise in therapeutics discovery and clinical drug development will be an invaluable asset as we progress our ambitious plans to drive the next era of precision therapeutics development.”
Katerina added: “Building on decades of genomics research, Enhanced’s 3D multi-omics platform has the potential to define causal biology, enabling the identification of high-confidence, first-in-class therapeutic targets to drive the development of truly disease-modifying therapies.”
